Notice for irinotecan (as sucrosofate) (Servier Laboratories (Aust) Pty Ltd)
Active ingredients
irinotecan (as sucrosofate)
Date of review outcome
Lapse date
Type
Priority review
Indication
First-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV)
Therapeutic area
Oncology